Does reduced eGFR cause higher plasma homocysteine levels?

The relationship between kidney function and homocysteine metabolism is well-documented, showing that as the estimated glomerular filtration rate (eGFR) declines, plasma homocysteine levels rise due to impaired clearance and altered metabolism.

Clinical and physiological evidence

Substantial evidence from clinical and epidemiological studies confirms a robust inverse correlation between eGFR and plasma homocysteine (Hcy) concentrations.

• Prevalence in CKD: In populations with chronic kidney disease (CKD), the prevalence of hyperhomocysteinemia increases dramatically as renal function worsens. Research indicates that while only about 10.73% of patients in CKD stage 1 have elevated Hcy, this figure rises to over 83.75% by stage 5.
• Concentration shifts: In advanced renal failure, mean Hcy concentrations often reach 17.1 μmol/L or higher. This elevation is primarily driven by renal impairment rather than dietary factors alone; while B-vitamin deficiencies can worsen the condition, supplementation often fails to normalize Hcy in patients with significant renal impairment, highlighting the dominance of the clearance deficit.
• Causality: Mendelian randomization analyses suggest a bidirectional or causal link, where genetically predicted higher homocysteine levels are associated with further reductions in eGFR and an increased risk of progressing CKD.

Mechanistic explanations

The kidneys are a primary site for the removal and processing of homocysteine through two integrated pathways that fail as eGFR drops:

• Filtration and Reabsorption: Homocysteine is freely filtered at the glomerulus. While a significant portion is reabsorbed in the tubules, the overall physical clearance rate is tethered to the glomerular filtration rate.
• Metabolic Degradation: Beyond simple filtration, the kidney is a major metabolic organ for Hcy, utilizing remethylation and transsulfuration pathways for intracellular breakdown. A reduced eGFR reflects a loss of functional nephron mass, which directly diminishes the kidney's capacity for this metabolic processing.
• Retention: Approximately 85% of CKD patients experience hyperhomocysteinemia because the rate of Hcy production eventually exceeds the combined filtration and metabolic capacity of the failing kidneys.

Bottom line

Reduced eGFR is a primary driver of elevated plasma homocysteine because it signifies a loss of both physical filtration and the metabolic capacity required to clear homocysteine from the blood. This association is a hallmark of progressive kidney disease.